MUC5AC is a glycoprotein with gel-forming properties, whose altered expression has been implicated in the pathogenesis of dry eye disease. The aim of our study was to achieve an efficient in vivo transfection of MUC5AC, restore its normal levels in an inflamed ocular surface and determine whether restored MUC5AC levels improve ocular surface inflammation. Cationized gelatin-based nanoparticles (NPs) loaded with a plasmid coding a modified MUC5AC protein (pMUC5AC) were instilled in healthy and experimental dry eye (EDE) mice. MUC5AC expression, clinical signs, corneal fluorescein staining and tear production were evaluated. Ocular specimens were processed for histopathologic evaluation, including goblet cell count and CD4 immunostaining. Neither ocular discomfort nor irritation was observed in vivo after NP treatment. Expression of modified MUC5AC was significantly higher in ocular surface tissue of pMUC5AC-NP-treated animals than that of controls. In healthy mice, pMUC5AC-NPs had no effect on fluorescein staining or tear production. In EDE mice, both parameters significantly improved after pMUC5AC-NP treatment. Anterior eye segment of treated mice showed normal architecture and morphology with lack of remarkable inflammatory changes, and a decrease in CD4 þ T-cell infiltration. Thus, pMUC5AC-NPs were well tolerated and able to induce the expression of modified MUC5A in ocular surface tissue, leading to reduction of the inflammation and, consequently improving the associated clinical parameters, such as tear production and fluorescein staining. These results identify a potential application of pMUC5AC-NPs as a new therapeutic modality for the treatment of dry eye disease.
INTRODUCTION
The ocular surface represents the interface between the eye and the outer world. It is defined as an anatomical, histological and physiological unit composed of the tear film and the corneal, limbal and conjunctival epithelia and adjacent connective tissues. The ocular surface along with the lacrimal glands and the interconnecting nervous, immune and endocrine systems form the lacrimal functional unit. 1 All components of the lacrimal functional unit are necessary to maintain the ocular surface homeostasis.
Dry eye syndrome is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. 2 Damage to any component of the lacrimal functional unit can result in dry eye, resulting in tear hyperosmolarity and tear film instability. Hyperosmolarity might cause damage to the ocular surface epithelium by activating a cascade of inflammatory events. Epithelial damage involves loss of goblet cells (GCs) and reduction in mucin secretion, and leads to tear film instability. This instability exacerbates ocular surface hyperosmolarity, thereby creating a vicious circle. 2 Mucins are a heterogeneous group of large glycoproteins found as major components in all mucous secretions. In the ocular surface they act as lubricants of the corneal and conjunctival epithelial surfaces during eyelid blinking, as stabilizers of the preocular tear film and as physical barrier to pathogen penetrance. 3 Inflammation can result in decreased mucin production. 4 Among mucins, MUC5AC is one of the most clinically relevant. MUC5AC is a highly glycosylated gel-forming mucin secreted by specialized epithelial cells of the conjunctiva, namely the GCs, which has a key role in tear homeostasis. 5 MUC5AC expression is decreased in several ocular diseases, such as keratoconjunctivitis sicca, Sjö gren syndrome, pemphigoid or Stevens-Johnson syndrome. 4, 6, 7 Dry eye syndrome is also accompanied by decreased MUC5AC expression and exhibits an abnormal pattern of protein glycosylation in GCs. 8 Because of its important role in the stability of the lacrimal fluid and its decreased expression in several ocular inflammatory conditions, MUC5AC could be a potential target for a new therapy for dry eye.
The eye is a promising candidate to benefit from gene therapy. Main reasons are its well-defined anatomy and accessibility. Promising results in the area of ocular gene therapy have already been reported. Acland et al performed successful RPE65 gene replacement therapy in natural canine models of Leber's congenital amaurosis that resulted in restoration of vision. 9 Adeno-associated virus-mediated transfer of soluble VEGF receptor 1 gene has been shown to reduce retinal neovascularization by 50%. 10 However, ocular gene therapy has remarkable limitations. To achieve efficient delivery of DNA to ocular surface cells, several barriers must be overcome, such as corneal and conjunctival epithelia and tear film, along with physiologic mechanism such as blinking or tear clearance, limiting the penetration of DNA into the eye. 11, 12 The use of nanoparticles (NPs) as carriers of therapeutic genetic material for delivery to target tissues and treatment of a wide range of ocular diseases has become popular in recent years. 13, 14 We recently described the use of NPs based on cationized gelatine (CG) and chondroitin sulphate (CS) to efficiently transfect corneal and conjunctival epithelial cells (PCT/ES2011/07078, priority date 14 November 2011). 15 These NPs were able to protect the plasmid DNA from degradation and have been shown to successfully induce plasmid internalization in ocular surface cells, thereby representing promising new carriers for gene delivery. 15 The purpose of this work was to achieve an efficient in vivo transfection of MUC5AC using cationized gelatine (CG)-based NPs, to restore MUC5AC levels in an inflamed ocular surface. Our hypothesis was that the normalization of the mucin levels would reduce the inflammation and break the mutually perpetuating pathogenetic mechanisms, which sustain the inflammatory state of the ocular surface in dry eye.
RESULTS
pMUC5AC-NPs induced the expression of modified MUC5AC in ocular surface tissues of healthy mice Hybrid NPs based on gelatine and CS were prepared by ionic gelation technique. The physicochemical properties of the blank NPs were 143 ± 10 nm and þ 34 ± 2 mV (for size and zeta potential, respectively), and for the pMUC5AC-NPs 128 ± 6 nm and þ 37±1 mV. MUC5AC mRNA expression was measured by real-time reverse-transcription PCR (RT 2 -PCR) to evaluate the ability of pMUC5AC-loaded NPs to produce an efficient transfection of ocular tissues in healthy mice. Mice treated with 2 mg per day of pMUC5AC (both naked pMUC5AC and pMUC5AC-NPs) did not show MUC5AC expression in either corneal or conjunctival epithelia (data not shown). Plasmid concentration was then increased to 4 mg per day, and significant expression of MUC5AC mRNA was detected in conjunctiva after 5 days of pMUC5AC-NPs treatment, whereas the cornea remained negative (Figure 1 ). pMUC5AC-NPs were well tolerated in ocular surface structures of healthy mice Clinical signs in all animals at all time points and with the two different plasmid concentrations were scored as grade 0 as none of the animals showed any ocular discomfort, irritation or swelling. There were also no macroscopically detectable alterations of the ocular surface.
To evaluate the tear physiology, tear production was measured in all animals before (baseline) and after the treatment (post). Although there were no statistically significant differences, there seemed to be a tendency toward an increase in the tear production after treatment with pMUC5AC-loaded NPs, at all time points and plasmid concentrations (Figure 2a) .
Corneal fluorescein staining was used as measurement of the effect of the different treatments on the corneal epithelial barrier function (Figure 2b) . No staining was observed in any animal. There were no differences between baseline and post-treatment fluorescein staining in any experimental group and among groups.
After all treatments, histopathology evaluation showed that corneal and conjunctival epithelia displayed normal cell layers and morphology (Figure 3a) . Conjunctival GCs were abundant, especially in the superior tarsal conjunctiva. The lacrimal glands also displayed normal architecture and morphology. No differences were observed among the different experimental groups.
All treated and control groups demonstrated complete lack of inflammatory changes, or focal mild alterations that were within the normal range and variations expected for healthy subjects.
Periodic acid-Schiff (PAS) staining showed showed a normal number of GCs along the conjunctiva in control mice (Figures 3b  and c) . No significant differences were detected in mice treated with naked plasmid and blank NPs. However, GC density was significantly higher in the pMUC5AC-NPs-treated mice compared with control mice, after both 3 and 5 day treatment. Therefore, pMUC5AC-NPs treatment increased GC numbers in healthy mice.
pMUC5AC-NPs induced the expression of modified MUC5AC in conjunctiva of EDE mice RT 2 -PCR revealed an increase in MUC5AC mRNA expression after pMUC5AC-NPs treatment for 5 days in both cornea and conjunctiva ( Figure 4 ). This increase was statistically significant in conjunctiva. No MUC5AC expression was detected in healthy mice, experimental dry eye (EDE) mice and EDE mice treated with blank NPs, whereas naked pMUC5AC-treated mice showed increased MUC5AC expression, although at significantly lower level than after pMUC5AC-NPs treatment.
pMUC5AC-NPs improved the inflammatory parameters associated with EDE No ocular discomfort, irritation or swelling was detected in any pMUC5AC-NPs-exposed animal. Therefore, the clinical signs in all of them were scored as grade 0. No edema, redness or corneal vascularization was observed in treated eyes. In addition, there were no visible macroscopic alterations of the ocular surface.
Tear production was measured in all animals, before EDE induction (baseline) and before (post EDE) and after the treatment . EDE produced a significant reduction in tear production in all animals. Controls without EDE did not display reduction in tear production. There were no significant differences between post EDE and post-treatment tear production in healthy mice, control EDE mice, EDE mice treated with naked plasmid and with blank NPs. However, after pMUC5AC-loaded NPs treatment, EDE mice tear production returned to baseline levels ( Figure 5a ). Therefore, the treatment with pMUC5AC-loaded NPs increased the tear production in EDE mice leading to normal baseline levels. Corneal fluorescein staining was performed before EDE (baseline) and before (post EDE) and after the treatment (post). Punctate and diffuse corneal fluorescein staining were observed in EDE animals, but not in the healthy controls. Whereas there were no changes after treatment in healthy mice, control EDE mice and EDE mice treated with naked plasmid or with blank NPs, the staining in mouse corneas treated with pMUC5AC-loaded NPs seemed to decrease (Figure 5b ).
To further evaluate the corneal epithelial barrier condition in the different experimental groups, the expression of two proteins implicated in tight junction complexes, zonula occludens protein 1 (ZO-1) and zonula occludens protein 2 (ZO-2), was analyzed by immunofluorescence ( Figure 5c ). In healthy control mice, ZO-1 and ZO-2 were located in the plasma membrane at cell-cell contacts in the most superficial layers of corneal epithelium. After EDE induction, ZO-1 and ZO-2 showed a predominant cytosolic localization in corneal epithelial cells. However, after pMUC5AC treatment, both proteins returned to the membrane localization, pointing out a reorganization of tight junction complexes.
In addition, phalloidin staining revealed changes in the distribution of actin cytoskeleton in corneal epithelium. In healthy mice, actin showed a well-structured corneal epithelium, whereas after EDE induction, the outer most epithelial layers showed an altered architecture ( Figure 5c ). pMUC5AC-NPs treatment seems to be able to reorganize the actin cytoskeleton of EDE mice, recovering the healthy mice corneal epithelium condition.
There were no significant differences between pro-inflammatory cytokine levels in healthy control mice and pMUC5AC-NPstreated mice, as determined by the cytokine multiplex assay (data not shown). This result suggests that pMUC5AC do not elicit an acute inflammatory response based on cytokine release. However, pMUC5AC-NPs-treated EDE mice showed similar cytokine levels than EDE control mice, without significant differences. Specifically, IFNg, IL-1b, and IL-2 levels were similar in both conditions, while IP-10 and TNFa showed a slight decrease in pMUC5AC-NPstreated EDE mice (IP-10: 9.78 ± 1.25 vs 4.28 ± 0.64 pg ml À 1 and TNFa: 27.93 ± 1.10 vs 14.29 ± 1.60 pg ml À 1 ), although the differences were not significant. Some cytokines were not detected in the collected tears, such as IL-6, IL-17 or RANTES, due to the sensitivity of the assay. All together, those data would indicate that pMUC5AC-NPs had no direct influence in short-term cytokine release and did neither improve nor exacerbate the inflammatory condition of EDE mice. 
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In the histopathology evaluation all specimens displayed an anterior eye segment with normal architecture and morphology ( Figure 6a ). The histopathologic changes observed ranged from complete lack of alterations to presence of focal mild and isolated inflammatory changes, which fell into the focal mild category. No animals from any experimental group displayed moderate or severe inflammatory changes.
GC numbers were normal along the conjunctiva in healthy mice. The distribution of the GC population within the conjunctiva is regional, with the highest density in the fornices, where these cells form clusters. In our study, GC density showed tendency toward decrease after EDE induction. Both blank NPs and pMUC5AC-NPs seemed to increase the GC numbers, but the detected differences did not reach statistical significance (Figures 6b and c) .
To further evaluate the inflammatory condition of the ocular surface tissue in the different experimental groups, CD4 imnunostaining was performed to identify Th cells ( Figure 7 ). No significant immunoreactivity for CD4 antibody (Ab) was detected in the conjunctiva of control healthy mice. However, EDE mice 2 -PCR, in EDE mice cornea and conjunctiva treated with pMUC5AC-NPs (EDE þ pMUC5AC-NPs) for 5 days. Controls include non-treated healthy mice (control), control EDE mice (EDE), EDE mice treated with naked plasmid (EDE þ naked pMUC5AC) and with blank NPs (EDE þ blank NPs). EDE mice treated with pMUC5AC-NPs showed significant MUC5AC expression in cornea and conjunctiva. *Po0.05.
showed remarkable CD4 þ T-cell infiltration of the conjunctival tissue. CD4 þ cells were apparent in the substantia propria and in the epithelium. After pMUC5AC-NPs treatment, no CD4 þ T cells were identified in mice conjunctiva. In order to refine the study, CD4 þ T-cell density was determined counting the positive CD4 cells along the whole conjunctiva. CD4 þ T-cell density significantly increased in EDE mice compared with healthy mice. pMUC5AC-NPs-treated mice showed a significant decrease in CD4 þ T cells, compared with EDE control mice, while neither naked pMUC5AC nor blank NPs had significant effect. No significant differences were detected between healthy mice and EDE mice treated with pMUC5AC-NPs.
DISCUSSION
In this study we evaluated the in vivo transfection capability of a new generation of cationized-based NPs loaded with a modified MUC5AC encoding novel plasmid (pMUC5AC-NPs) in ocular tissues, in order to normalize mucin levels in an inflamed ocular surface. We also studied whether the mucin level normalization might lead to improvement in the clinical signs associated with ocular inflammation and ultimately alleviate the inflammatory process. We found that pMUC5AC-NPs were well tolerated and induced the expression of modified MUC5AC in ocular surface structures, both in healthy and EDE mice. In addition, the mucin level normalization led to the abolishment of the inflammation and to a remarkable improvement of the associated clinical signs. CG-based NPs were used as plasmid carriers. NPs are recognized as promising genetic delivery systems. There are several studies in which NPs have been used for ocular gene therapy. 16 However, most of them reported significant difficulties associated with toxicity, an invasive way of administration, or low ability to achieve target cells. The hybrid NPs composed of CG and the natural polyanion CS, associated with the modified MUC5AC encoding plasmid have been previously tested in vitro and reported as suitable systems for ocular cells gene therapy. 11, 12 The small size Figure 5 . Condition of ocular surface before EDE (baseline) and before (post EDE) and after pMUC5ac-NPs treatment (post). Controls include non-treated healthy mice (control), control EDE mice (EDE), EDE mice treated with naked plasmid (EDE þ naked pMUC5AC) and with blank NPs (EDE þ blank NPs). (a) EDE produced a significant reduction in tear production in all animals. After pMUC5AC-loaded NPs treatment, tear production significantly increased and returned to baseline level (*Po0.05 vs baseline; 
and the positive zeta potential (approximately þ 30 mV) of NPs has been described to improve its uptake by epithelial cells 17 and increase the interactions with the ocular epithelia 18 achieving an efficient in vitro MUC5AC transfection without compromising the cell viability. 15 MUC5AC was chosen as a potential target for this therapy due to its important role in the stability of the lacrimal fluid and its decreased expression in several ocular inflammatory conditions. 8 Our study results demonstrated that treatment with 4 mg per day of pMUC5AC-NPs for 5 days was able to induce the expression Figure 6 . (a) Light micrographs of hematoxylin and eosin (HE)-stained tissue sections from healthy control mice, EDE mice and EDE mice treated with naked pMUC5AC, blank NPs and pMUC5AC-NPs-treated tissue sections. Representative corneal, conjunctival and lacrimal gland sections showed normal cell layers, no alterations in epithelial morphology and focal mild inflammatory changes in the EDE groups, which completely disappeared after MUC5AC-NPs treatment. Original magnification Â 20. (b) GC density along conjunctiva in EDE mice treated with pMUC5AC-NPs. Representative light micrographs of conjunctival Alcian blue-PAS-stained sections (b) and GC count bar charts (c) showed a decrease in GC density after EDE induction and a trend toward an increase in GC density after pMUC5AC-NPs. Scale bar: 50mm. *Po0.05. Arrowhead: goblet cells. ep, epithelium; st, stroma. This observation is in agreement with our previous in vitro experience with these nanosystems. 15 It is important to point out that this is one of the first in vivo works that achieved effective transfection of ocular epithelia, with topical treatment of a therapeutic plasmid using non-viral vectors. Indeed, previous works have been reported successful transfection in corneal and conjunctival epithelial cells using model, non therapeutic plasmids. 19, 20 In contrast, pMUC5AC-NPs led to a significant increase in the expression of a functional human protein, the modified MUC5AC protein, in mice ocular surface epithelia.
Neither ocular discomfort nor irritation was observed in vivo after pMUC5AC-NP treatment. No significant effects were detected on fluorescein staining or tear production either. Besides, treated mice showed normal morphology and a complete lack of inflammatory changes. Furthermore, pMUC5AC-NPs seem to improve some clinical and histologic parameters: pMUC5AC-NPs treatment significantly increased the GC numbers in healthy mice and there seemed to be a tendency toward an increase in tear production after treatment with the pMUC5AC-loaded NPs. Based upon the absence of histopathologic and functional alterations of the ocular surface, pMUC5AC-NPs seem to be nonhazardous and have excellent tolerance in all ocular tissues. These results were expected as each administration was below the toxic in vitro concentration attributed to these NPs according to studies in human corneal epithelial cells. 21 Other evidences of the safe application of NPs to the ocular surface have been reported. 22 Once pMUC5AC-NPs were shown to be well tolerated, and to induce the expression of modified MUC5AC in the ocular surface tissues of healthy mice, pMUC5AC-NPs were tested in a wellestablished murine model of ocular inflammation (EDE). EDE was induced in mice through exposure to desiccating stress and scopolamine injections. EDE animals have been described to develop ocular surface lesions that mimic those found in dry eye patients: corneal fluorescein staining, reduced tear production, decreased conjunctival GC density and CD4 þ T-cell infiltration of the conjunctiva. 23 In this work, EDE mice demonstrated: (1) weak fluorescein staining attributable to a slight disturbance in the corneal epithelial barrier; (2) a significant decrease in tear production; (3) no significant change in GC density, although some apparent tendency toward decrease was observed; and (4) a significant increase in the CD4 þ T cells in the conjunctiva. These findings agree with those previously reported, but in our study they were less pronounced. It is to be noted that EDE induction was performed for only 10 days, which resulted in the EDE mice being in a very early stage of the disease. The experimental animals would certainly require a more prolonged period of follow-up to manifest to a full extent the whole range of ocular surface lesions characteristic of dry eye.
The histopathologic evaluation of the EDE mice revealed normal morphology and focal mild inflammatory changes. These results are compatible with the expected morphological changes in a chronic inflammatory condition in a very early stage. In the context of our histopathologic findings, it is to be noted that the dry eye syndrome is a chronic condition, which develops over a long period of time, and it could manifest clinically initially without the presence of pronounced inflammatory changes. The development of some of the other histopathologic features characteristic of dry eye, such as stromal fibrosis and epithelial keratinization, would require a more prolonged period of followup to become morphologically apparent.
pMUC5AC-NPs were able to induce MUC5AC mRNA expression in EDE mice. This expression was significantly higher than in untreated control animals in both cornea and conjunctiva. Corneal tissue of EDE mice expressed MUC5AC, whereas in healthy mice MUC5AC expression was not detected. The alteration of the corneal barrier integrity caused by the inflammatory process, which has been previously reported (manuscript submitted), might ease the NP internalization and, therefore, increase the transfection efficiency and MUC5AC expression. 
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Regarding the condition of the ocular surface, in EDE mice, pMUC5AC-NP treatment was able to: (1) improve the integrity of the corneal epithelial barrier; (2) increase tear production; (3) show a tendency toward increase in the GC numbers; and (4) decrease the CD4 þ T-cell infiltration in the conjunctiva.
Fluorescein staining is a routine clinical test used to determine corneal integrity in patients. When corneal epithelial cell-cell junctions are disrupted and/or corneal epithelial cells are damaged, a fluorescein uptake occurs resulting in a visible staining. 24 That disruption renders the ocular surface susceptible to environmental insults. The staining in EDE mouse corneas treated with pMUC5AC-NPs seemed to decrease. These results suggest that pMUC5AC-NPs treatment might be responsible for the improvement of the integrity of the ocular epithelial barrier in EDE mice. The mechanisms by which MUC5AC preserves corneal barrier function remains to be fully determined, although our previously reported studies may have provided some clues. In our earlier experiments, simulated inflammatory conditions in vitro, similar to those in EDE mice, led to alterations of the corneal barrier by modulating tight junctions protein composition. 25 In EDE mice, the tight junction proteins, ZO-1 and ZO-2, in addition of actin cytoskeleton were altered, too. The anti-inflammatory cytokine IL-10 was able to reverse these conditions and reinstate the barrier integrity. 25 In a similar manner, pMUC5AC-NPs were also able to decrease the inflammatory reaction and possibly acting through the same mechanism of alleviating the inflammation, they successfully restored the corneal barrier function and integrity. Improvements in this barrier property are also observed in other classical dry eye anti-inflammatory therapy with corticoids and cyclosporine A, and seem to have an important role in the reestablishment of normal lacrimal function. 26 Measurement of tear secretion is one of the parameters more widely used in the diagnosis of dry eye. The treatment with pMUC5AC-NPs increased the tear production in EDE mice to normal baseline levels. The fact that blank NPs and free plasmid did not increase tear production suggests that the change observed for the pMUC5AC-NPs was due to expression of MUC5AC protein, and not due an intrinsic irritating process in the eye. There is no reliable evidence to indicate how MUC5AC increases tear production in the eye, but it might be related to a higher tear quality. Owing to their hydrophilic character, mucins participate in the prevention of the desiccation of the ocular surface through water retention. 24 Therefore, an increased expression of MUC5AC could have led to an improved tear film quality with a subsequent decrease in evaporation. Currently, there is only one formulation approved by the Food and Drug Administration able to increase natural tear production (0.05% cyclosporine emulsion; Restasis, Allergan Inc., Irvine, CA, USA).
GC density is another critical parameter that reflect the overall health of the ocular surface. 27 Cytologic studies have indicated that decreased GC density is a consistent finding in dry eye in humans. 28 Although GC density did not significantly change after pMUC5AC-NPs, there was an apparent tendency toward an increase in the GC numbers. Taking into account that EDE mice were in a very early stage of the disease, more prolonged EDE model might be required to observe significant changes in GC density, both after EDE induction and after pMUC5AC-NPs treatment.
No major histopathology alterations and only focal mild inflammatory changes were detected in EDE mice, before or after pMUC5AC-NPs treatment. However, EDE mice demonstrated remarkable CD4 þ T-cell infiltration in conjunctiva. pMUC5AC-NPs-treated mice demonstrated a statistically significant decrease in CD4 þ T-cell numbers, comparable to those of healthy mice. CD4 þ T cells are the most important inflammatory cells implicated in the development of dry eye syndrome. 29 This important fact partially explains the ability of pMUC5AC-NPs to effectively reduce the inflammation in EDE mice. The exact mechanism by which MUC5AC achieved the abolishment of the inflammatory response is not clear. Our hypothesis in this regard is that an increase in MUC5AC expression might have potential role in the process of hiding of key epitopes needed to trigger the inflammatory process. Indeed, it is reported that some secreted mucin can block the interaction among antigen epitopes and Abs because of esteric hindrance. 30, 31 On the basis of these data, we propose that normalization of MUC5AC levels leads to effective reduction of the inflammation and to break the vicious cycle of dry eye (Figure 8 ). Normalized MUC5AC level has positive influence on the tear film quality and properties. Through increasing water retention, MUC5AC would reduce the tear evaporation and would improve the tear film stability and osmolarity. Maintaining normal osmolarity is an important part of sustaining the healthy state of the ocular surface as it impedes and prevents the activation of new inflammatory events. Therefore, the proposed strategy could be considered as the first effective treatment for dry eye that is not based in a classical anti-inflammatory molecule.
In conclusion, pMUC5AC-NPs were well tolerated and able to induce the expression of modified MUC5A in murine ocular Figure 8 . Proposed mechanism implicated in the reduction of the inflammation and the rupture of the vicious cycle of dry eye after pMUC5AC-NPs treatment. The normalization of MUC5AC levels would improve the tear film quality, reduce the tear evaporation, increase the tear film stability and regulate tear osmolarity. A normal osmolarity might not activate new inflammatory events in the ocular surface.
pMUC5AC-loaded NPs for the treatment of EDE L Contreras et al surface tissue. This is a proof-of-concept of a safe topical transfection of ocular surface cells using non-viral recently designed nanocarriers. Moreover, expression of the novel MUC5AC plasmid in diseased EDE mice correlated with significant reduction of the inflammation and, consequently, to remarkable improvement of the clinical parameters associated with this condition including improvement of the integrity of the corneal epithelial barrier, increasing the tear production and GC numbers, and reducing the CD4 þ T-cells infiltration in the conjunctiva. These results provide strong evidence in support of the potential use of pMUC5AC-NPs as a new therapeutic modality for dry eye disease.
MATERIALS AND METHODS Mice
All studies adhered the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research. Protocols were approved by the Institutional Board and supervised by an expert in animal health care. Female C57BL/6 mice (Jackson Laboratory, Sacramento, CA, USA), 6-8 weeks old, were used in these studies. Both eyes were used to reduce numbers of animals.
Materials
Type A gelatine (137 kDa) was generously gifted from Nitta Gelatin (Ontario, Canada). N-(3-Dimethylaminopropyl)-N 0 -ethylcarbodiimide hydrochloride, tripolyphosphate, and spermine hydrochloride were purchased from Sigma-Aldrich (Madrid, Spain). CS was purchased from Calbiochem (Darmstadt, Germany). The plasmid pMUC5AC, which codifies a modified MUC5AC protein and, optionally also, the green fluorescent protein as a marker, was designed by our group (PCT/ES2011/07078, priority date 14 November 2011) and supplied by Biomedal (Sevilla, Spain) pMUC5AC-loaded NPs (pMUC5AC-NPs) NPs were formed using the ionic gelation technique. 32 The gelatine was cationized with spermine trough a carbodiimine reaction as previously described. 33 CG was dissolved in water at a concentration of 1 mg ml À 1 , CS at a concentration of 0.125 mg ml À 1 and tripolyphosphate at a concentration of 0.125 mg ml À 1 . All solutions were prepared in water and sterilized by filtration (0.22 mm, MillexGV, Millipore, Billerica, MA, USA). The pMUC5AC plasmid and CS solution were incorporated into the tripolyphosphate solution. NPs were obtained by adding the resulting mix to the CG solution with magnetic stirring at room temperature (RT) and isolated by centrifugation (Beckman CR412, Beckman Coulter, Brea, CA, USA) at 10 000 r.c.f. for 30 min at 4 1C with 0.1% (v/v) glycerol. NPs were then resuspended in water at a final plasmid concentration of 0.2 mg ml À 1 (PCT/ES2011/07078). The mean particle size was determined by photon correlation spectroscopy and the zeta potential was obtained by laser Doppler anemometry measuring the mean electrophoretic mobility. Both assays were performed in using a Zetasizer Nano ZS (Malvern, UK).
Tolerance study
To determine the tolerance of mice ocular surface structures to the exposure of pMUC5AC-NPs, healthy animals (n ¼ 20, 5 per group) received instillations (5 ml) of: (1) naked plasmid; (2) blank NPs; or (3) pMUC5AC-loaded NPs in both eyes four times a day during 3 or 5 days. Two different concentration of pMUC5AC were tested: 2 and 4 mg per day. Control animals, receiving no instillations, were included in the study as additional controls. Three independent experiments were performed.
Forty-eight hours after the last instillation, MUC5AC mRNA expression was measured in cornea and conjunctiva by RT 2 -PCR. The ocular tolerance to the different treatments were evaluated using: (a) macroscopic evaluation of clinical signs; (b) fluorescein staining of the ocular surface (comparing pre-and post-treatment); (c) tear production (pre-and posttreatment); (d) tear collection for cytokine study; and (e) histopathologic evaluation of ocular tissues.
Murine EDE EDE was induced in C57BL/6 mice by injecting scopolamine (0.5 mg in 0.2 ml) (Sigma-Aldrich) subcutaneously three times a day in alternative flank for 10 days as previously described. 23 Mice cages were placed in front of a fan directed to blow across the wired screen side of the cage 24 h a day with controlled humidity (o40%).
EDE animals (n ¼ 20; 5 per group) were distributed in four experimental groups: (1) control: no topical treatment received; (2) naked plasmid: 0.2 mg ml À 1 of naked pMUC5AC (total of 4 mg of pMUC5AC per day); (3) blank NPs; (4) pMUC5AC-loaded NPs group: 0.2 mg ml À 1 of pMUC5AC-loaded NPs (total of 4 mg of pMUC5AC per day). In all groups, mice received 5 ml per eye bilaterally four times a day. A healthy mice group (n ¼ 5) was added as an additional control (no topical treatment received).
After 5 days under desiccating conditions and scopolamine injections, the different treatments were started in all experimental groups for 5 days, keeping the dry eye conditions at the same time. 48 h later, tears and tissues were collected. In addition, tear production and fluorescein staining were performed three times at different time points: (1) 24 h before starting the dry eye induction (baseline measurement); (2) at day 5, just after starting the different treatments (dry eye measurement); and (3) and at day 10, the end of treatments (after treatment measurement). Two independent experiments were performed.
Clinical signs evaluation
A macroscopic evaluation of the ocular structures to determine the presence of clinical signs, including ocular discomfort, presence of corneal and/or conjunctival alterations, mucous discharge and lid swelling, was performed daily, using a grading scale of 0-2, following the criteria described in Table 1 . 22 
Tear production
Tear production was measured with sterile cotton threads (ZoneQuick Thread, Oasis Medical, Glendale, CA, USA). Threads, which turn red when absorbance of tears occurs, were held with forceps into the inferior conjunctival sac for 30 s. Afterwards, the threads were removed and the distance of redness was measured in millimeters.
Corneal fluorescein staining
Corneal fluorescein staining was evaluated and photographed, in isoflurane sedated mice, with a slit lamp biomicroscope using a cobalt blue light 1 min after application of 1ml of 10mg ml À 1 sodium fluorescein (Sigma-Aldrich).
Tear collection and cytokine measurement
A volume of 0.5 ml of Beadlyte Assay Buffer (Millipore) were applied to the ocular surface. Tear fluid (2 ml) was then collected by placing a glass capillary tube in the tear meniscus at the canthus of both eyes. Ten inflammatory cytokines and chemokines (IFNg, TNFa, RANTES, IP-10, IL-1b, IL-2, IL-6, IL-10, IL12p70 and IL-17) were evaluated in tear fluid with a 10X-multiplex immunobead-based assay (MPXMCYTO-70K MILLIPLEX MAP Mouse Cytokine/Chemokine Panel, Millipore). Cytokine multiplex bead assay was done following the manufacturer's protocol. Briefly, 10 ml of each diluted (1/5 in assay buffer) sample were incubated overnight on a plate 
Histopathology study
Mice were euthanized by CO 2 inhalation and their eye balls with attached eyelids and lacrimal glands were excised. Eye tissues were embedded in optimal cutting temperature compound, frozen and sectioned with a cryostat (7 mm). Tissue samples were also fixed in 4% paraformaldhehyde, embedded in paraffin and sectioned (4 mm). Sections were then stained with hematoxylin and eosin and Alcian blue-PAS. Conjunctival and corneal epithelial morphology were evaluated. Histopathology evaluation of the specimens was carried out by a pathologist (co-author DH) in a masked manner, including cornea, conjunctiva, anterior eye segment, orbital soft tissue and lacrimal gland. Conjunctival GC numbers were counted in a masked manner by two independent trained observers, in the superior and inferior bulbar and tarsal conjunctivas, using an Â 20 objective. Sections from both eye balls of three experimental animals from each group (in three different sets of experiments) were examined and photographed.
RNA isolation and RT 2 -PCR
Total RNA from corneal and conjunctival epithelia collected and pooled from each group (six eyes per group per experiment) were isolated following the guanidium thiocyanate-phenol-chloroform extraction method (Trizol, Invitrogen, Carlsbad, CA, USA). RNA concentration was measured by its absorbance at 260 nm and stored at À 80 1C before used. cDNA was generated form 1 mg of total RNA with the SuperScript VilocDNA kit (Invitrogen), according to the manufacturer's protocol. 
Immunofluorescence assays
Optimal cutting temperature-embedded eye balls with attached eyelids were cryosectioned at 7 mm and fixed in À 20 1C acetone for 10 min. They were incubated at RT for 50 min with blocking buffer composed of phosphate-buffered saline (PBS) with 4% donkey serum, 0.3% Triton X-100 and 1% bovine serum albumin (all from Sigma-Aldrich) to block nonspecific binding. Afterwards, they were incubated with the primary Abs ZO-1 (2.5 mg ml À 1 ) and protein 2 (ZO-2; 4 mg ml À 1 ) (both from Invitrogen) for 1 h at RT. Alexa Fluor 488-conjugated secondary Ab (20 mg ml À 1 ; Invitrogen) were used and after washing, sections were mounted and coversliped for microscopy examination. Each experiment was performed three times and negative controls included the omission of primary Abs.
In addition, tissue sections were stained with rhodamine-conjugated phalloidin (Invitrogen), which targets cytoskeletal actin network. Briefly, cells were fixed in ice-cold methanol, permeabilized in 5% Triton X-100 and stained with 10 U ml À 1 phalloidin. After 30 min of incubation, cells were washed in PBS before microscopy examination. Fluorescence was visualized with a Leica TCS SPE confocal laser microscope equipped with a solid state laser with a 488-nm excitation filter (Leica Microsystems, Wetzlar, Germany). Cells were observed under a dry Â 40 objective with a pinhole size of 1 (optical slice thickness was 1.7 mm). Each experiment was performed three times and negative controls included omission of primary Abs.
CD4 immunostaining
Optimal cutting temperature-embedded eye balls with attached eyelids were cryosectioned at 7mm and fixed in À 20 1C acetone for 10 min. Slides were treated with 0.3% hydrogen peroxide for 10 min, air dried at RT for 1 h and rinsed in PBS. Sections were then blocked with 20% normal rabbit serum (Dako, Carpinteria, CA, USA) in PBS for 1 h at RT, rinsed in PBS and incubated with primary Ab Rat anti-Mouse CD4 (BD Pharmingen, Sparks, MD, USA) at RT for 1 h to determine the presence of Th cells. Subsequently, sections were incubated with the biotinylated polyclonal secondary Ab anti-Rat Ig (BD Pharmigen) for 30 min at RT. Vectastain Elite ABC reagents (Vector Laboratories, Burlingame, CA, USA) were applied to the tissue for antigen localization. Sections were counterstained with hematoxylin. Negative controls were performed without primary Ab. In addition, an isotope control (Rat IgGak, BD Pharmigen) was performed. CD4 positive cell numbers in conjunctiva were counted in a masked manner by two independent trained observers, using an Â 40 objective. Three sections from the eye balls of three animals from each group (in three different sets of experiments) were examined and photographed.
Statistical analysis
Repeated measures analysis of variance (ANOVA) was performed for tear production data. Two way ANOVA was performed for the remaining data. Results were expressed as mean ± s.e.m. Differences were considered to be significant when *Po0.05.
